Format

Send to

Choose Destination
Oncotarget. 2016 Feb 9;7(6):6410-23. doi: 10.18632/oncotarget.7064.

Extracorporeal Shock Wave Treatment (ESWT) enhances the in vitro-induced differentiation of human tendon-derived stem/progenitor cells (hTSPCs).

Author information

1
Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy.
2
Cellular Diagnostics Unit, Sant'Andrea Hospital, Rome, Italy.
3
Department of Orthopedics and Traumatology, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy.
4
Department of Biomedicine and Prevention, Laboratory of Signal Transduction, "Tor Vergata" University of Rome, Rome, Italy.

Abstract

Extracorporeal shock wave therapy (ESWT) is a non-invasive and innovative technology for the management of specific tendinopathies. In order to elucidate the ESWT-mediated clinical benefits, human Tendon-derived Stem/Progenitor cells (hTSPCs) explanted from 5 healthy semitendinosus (ST) and 5 ruptured Achilles (AT) tendons were established. While hTSPCs from the two groups showed similar proliferation rates and stem cell surface marker profiles, we found that the clonogenic potential was maintained only in cells derived from healthy donors. Interestingly, ESWT significantly accelerated hTSPCs differentiation, suggesting that the clinical benefits of ESWT may be ascribed to increased efficiency of tendon repair after injury.

KEYWORDS:

ESWT; Pathology Section; differentiation; healing; stem cells; tendon

PMID:
26843618
PMCID:
PMC4872723
DOI:
10.18632/oncotarget.7064
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center